Novartis/BMS deal closes
This article was originally published in The Tan Sheet
Swiss firm completes $385 mil. strategic acquisition of Mead Johnson's global adult nutritionals business from Bristol-Meyers Squibb Feb. 13. Novartis said the all-cash deal did not require any divestments for regulatory approval. The firms announced the deal in December (1"The Tan Sheet" Dec. 22, 2003, p. 12)...
You may also be interested in...
The divestiture of Mead Johnson's adult nutritionals business to Novartis Medical Nutrition will allow the Bristol-Myers Squibb division to concentrate on its infant formula franchise
Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.
Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents
Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.